Research in Medicinal Chemistry
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".
Deadline for manuscript submissions: closed (26 May 2023) | Viewed by 2039
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is one of the leading causes of death worldwide. Despite the significant number of discoveries in this field, there is still a great necessity for novel, selective and advanced treatment to cure cancer efficiently. Researchers from all over the world continue to work to identify new drugs that can cure cancer with minimal or no side effects. Chemotherapy is one of the commonly used cancer treatments. Several of the chemical entities involved in chemotherapy contain heterocycles, especially azaheterocycle scaffolds. The azaheterocycles exhibit their anticancer activity by targeting tubulin, kinase, DNA, histone deacetylases (HDACs), signal transducer and activator of transcription (STAT), poly-adenosine diphosphate-ribose polymerase (PARP), etc. Over the past few decades, the nitrogen heterocycles, such as pyrrole, indole, benzimidazole, pyridine, pyrimidine, oxadiazole, thiazole, thiadiazol, oxazole, imidazole, pyrazoles, triazoles, etc., have been extensively used in anticancer drug discovery. However, despite the wide range of antitumor activities associated with azaheterocycles, still there remains a requirement to identify novel azaheterocycles with improved and selective anticancer activity, which has become an important aim in modern cancer drug discovery.
The advent of new chemical entities, approaches, and treatments has brought new opportunities for anticancer drug discovery. With this Special Issue, we aim to provide an overview of recent advances in the development of azaheterocycles in modern cancer drug discovery to the scientific community from academia and industry.
Dr. Mukund Tantak
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- azaheterocycles
- cancer drug discovery
- drug target
- anticancer agents
- chemotherapy
